Discovery of retinoic acid receptor agonists as proliferators of cardiac progenitor cells through a phenotypic screening approach

Author:

Drowley Lauren1,McPheat Jane2,Nordqvist Anneli1,Peel Samantha3,Karlsson Ulla2,Martinsson Sofia1,Müllers Erik1,Dellsén Anita2,Knight Sinead3,Barrett Ian3,Sánchez José2,Magnusson Björn2,Greber Boris4,Wang Qing-Dong1,Plowright Alleyn T.1

Affiliation:

1. Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, Gothenburg, Sweden

2. Discovery Sciences R&D, AstraZeneca, Gothenburg, Sweden

3. Discovery Sciences R&D, AstraZeneca, Cambridge, UK

4. Human Stem Cell Pluripotency Laboratory Max Planck Institute for Molecular Biomedicine, Münster, Germany

Abstract

Abstract Identification of small molecules with the potential to selectively proliferate cardiac progenitor cells (CPCs) will aid our understanding of the signaling pathways and mechanisms involved and could ultimately provide tools for regenerative therapies for the treatment of post-MI cardiac dysfunction. We have used an in vitro human induced pluripotent stem cell-derived CPC model to screen a 10,000-compound library containing molecules representing different target classes and compounds reported to modulate the phenotype of stem or primary cells. The primary readout of this phenotypic screen was proliferation as measured by nuclear count. We identified retinoic acid receptor (RAR) agonists as potent proliferators of CPCs. The CPCs retained their progenitor phenotype following proliferation and the identified RAR agonists did not proliferate human cardiac fibroblasts, the major cell type in the heart. In addition, the RAR agonists were able to proliferate an independent source of CPCs, HuES6. The RAR agonists had a time-of-differentiation-dependent effect on the HuES6-derived CPCs. At 4 days of differentiation, treatment with retinoic acid induced differentiation of the CPCs to atrial cells. However, after 5 days of differentiation treatment with RAR agonists led to an inhibition of terminal differentiation to cardiomyocytes and enhanced the proliferation of the cells. RAR agonists, at least transiently, enhance the proliferation of human CPCs, at the expense of terminal cardiac differentiation. How this mechanism translates in vivo to activate endogenous CPCs and whether enhancing proliferation of these rare progenitor cells is sufficient to enhance cardiac repair remains to be investigated. Significance statement Progenitor cells are rare and difficult to isolate, and little is known about the molecular mechanisms required for their proliferation and differentiation. Identification of small molecules that selectively proliferate cardiac progenitor cells will aid in the understanding of the signaling mechanisms involved and could provide tools for regenerative therapies for the treatment of cardiac dysfunction. A phenotypic screen identified retinoic acid receptor agonists as potent proliferators of induced pluripotent stem cell-derived cardiac progenitor cells. The agonists did not proliferate human cardiac fibroblasts, the major cell type in the heart but did proliferate human pluripotent stem cells, HuES6, in a time-of-differentiation-dependent manner.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3